- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05226897
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
May 30, 2022 updated by: Yooyoung Pharmaceutical Co., Ltd.
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of YYC405-T Added to Metformin and Dapagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With the Combination of Metformin and Dapagliflozin
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Phase 3 study to assess the Efficacy and Safety of YYC405-T when added to Metformin and Dapagliflozin combination therapy in patients with type 2 diabetes mellitus who have inadequate glycemic control
Study Type
Interventional
Enrollment (Anticipated)
256
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bucheon, Korea, Republic of
- The Catholic University of Korea(Bucheon St. Mary's Hospital)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient who contsent to participate in this tiral by written informed consent form
- A man or woman over 20 years old
- Type 2 Diabetes patients
Exclusion Criteria:
- Patients with severe renal impairment, end-stage renal disease or on dialysis
- Type 1 diabetes patients
- Patients with a history of acute or chronic target acidosis, including lactic acidosis and diabetic ketoacidosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Test
Take YYC405-T and Metformin≥1000mg, Dapagliflozin 10mg
|
Subjects take the investigational products once a day for 24 weeks.
Subjects take the investigational products once a day for 24 weeks.
Subjects take the investigational products once a day for 24 weeks.
|
PLACEBO_COMPARATOR: Placebo control
Take YYC405-T Placebo and Metformin≥1000mg, Dapagliflozin 10mg
|
Subjects take the investigational products once a day for 24 weeks.
Subjects take the investigational products once a day for 24 weeks.
Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: Baseline, 24 weeks
|
Change from baseline in Glycosylated Hemoglobin (HbA1c)
|
Baseline, 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: Baseline, 12weeks
|
Change from baseline in Glycosylated Hemoglobin (HbA1c)
|
Baseline, 12weeks
|
FPG, Fasting insulin
Time Frame: Baseline, 12weeks, 24weeks
|
Change from baseline in Fasing plasma glucose and Fasting insulin
|
Baseline, 12weeks, 24weeks
|
C-peptide
Time Frame: Baseline, 12weeks, 24weeks
|
Change from baseline in C-peptide
|
Baseline, 12weeks, 24weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Sungrae Kim, MD, Ph.D, Bucheon St Mary Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 12, 2021
Primary Completion (ANTICIPATED)
October 31, 2022
Study Completion (ANTICIPATED)
June 26, 2023
Study Registration Dates
First Submitted
January 17, 2022
First Submitted That Met QC Criteria
February 3, 2022
First Posted (ACTUAL)
February 7, 2022
Study Record Updates
Last Update Posted (ACTUAL)
June 1, 2022
Last Update Submitted That Met QC Criteria
May 30, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YYPCT_YYC405_301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
University of Campania "Luigi Vanvitelli"CompletedType 2 Diabetes MellitusItaly
-
Population Health Research InstituteNovo Nordisk A/SCompletedType 2 Diabetes MellitusCanada
-
Northwell HealthPatient-Centered Outcomes Research InstituteCompletedType 2 Diabetes Mellitus | Type 2 DiabetesUnited States
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusChina
-
University of MinnesotaUniversity of Southern California; Wake Forest UniversityCompleted
-
Joslin Diabetes CenterDHR Health Institute for Research and Development; Verizon FoundationCompletedType 2 Diabetes MellitusUnited States
Clinical Trials on Metformin≥1000mg
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Handok Inc.CompletedHealthy VolunteersKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Dong-A ST Co., Ltd.UnknownDiabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease | Renal DiseaseKorea, Republic of
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
GC Biopharma CorpRecruitingHealthy VolunteersKorea, Republic of
-
GC Biopharma CorpRecruitingHealthy VolunteersKorea, Republic of
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of